The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

- Formoterol & Beclomethasone (R03AK08),

- Ambrisentan (C02KX02),

- Chlorprothixen (N05AF03),

- Biperiden (N04AA02),

- Paracetamol (N02BE01),

- Ebastine (R06AX22),

- Tramadol & Paracetamol (N02AJ13),

- infliximab (L04AB02).

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations, subject to uniform contractual conditions and a standardized access procedure.

The earliest contract start is 1/1/2021. Based on this, the contract term is a maximum of 24 months.

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations, subject to uniform contractual conditions and a standardized access procedure.

The earliest contract start is 1/1/2021. Based on this, the contract term is a maximum of 24 months.